Peptide-Based Vaccines for Tuberculosis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Feb 17

PMID 35173740

Authors

Wenping Gong

Chao Pan

Peng Cheng

Jie Wang

Guangyu Zhao

Xueqiong Wu

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is an infectious disease caused by . As a result of the coronavirus disease 2019 (COVID-19) pandemic, the global TB mortality rate in 2020 is rising, making TB prevention and control more challenging. Vaccination has been considered the best approach to reduce the TB burden. Unfortunately, BCG, the only TB vaccine currently approved for use, offers some protection against childhood TB but is less effective in adults. Therefore, it is urgent to develop new TB vaccines that are more effective than BCG. Accumulating data indicated that peptides or epitopes play essential roles in bridging innate and adaptive immunity and triggering adaptive immunity. Furthermore, innovations in bioinformatics, immunoinformatics, synthetic technologies, new materials, and transgenic animal models have put wings on the research of peptide-based vaccines for TB. Hence, this review seeks to give an overview of current tools that can be used to design a peptide-based vaccine, the research status of peptide-based vaccines for TB, protein-based bacterial vaccine delivery systems, and animal models for the peptide-based vaccines. These explorations will provide approaches and strategies for developing safer and more effective peptide-based vaccines and contribute to achieving the WHO's End TB Strategy.

Citing Articles

In-silico development of a novel TLR2-mediating multi-epitope vaccine against .

Singh S, Verma P, Gaur M, Bhati L, Madan R, Sharma P In Silico Pharmacol. 2025; 13(1):34.

PMID: 40018380 PMC: 11861476. DOI: 10.1007/s40203-025-00322-8.

Development of a Vaccine Candidate Based on Surface-Displayed Particles of from the MTB39A Protein.

Wang P, Zhang G, Jiang L, Zhang S, Gao W, Wu Z Int J Mol Sci. 2025; 26(2.

PMID: 39859511 PMC: 11766116. DOI: 10.3390/ijms26020797.

Tuberculosis vaccines and therapeutic drug: challenges and future directions.

An Y, Ni R, Zhuang L, Yang L, Ye Z, Li L Mol Biomed. 2025; 6(1):4.

PMID: 39841361 PMC: 11754781. DOI: 10.1186/s43556-024-00243-6.

Leveraging computer-aided design and artificial intelligence to develop a next-generation multi-epitope tuberculosis vaccine candidate.

Zhuang L, Ali A, Yang L, Ye Z, Li L, Ni R Infect Med (Beijing). 2024; 3(4):100148.

PMID: 39687693 PMC: 11647498. DOI: 10.1016/j.imj.2024.100148.

analysis for the development of multi-epitope vaccines against .

Yun J, Kim A, Kim S, Shin E, Ha S, Kim D Front Immunol. 2024; 15:1474346.

PMID: 39624097 PMC: 11609213. DOI: 10.3389/fimmu.2024.1474346.

References

Liang Y, Bai X, Zhang J, Song J, Yang Y, Yu Q . Ag85A/ESAT-6 chimeric DNA vaccine induces an adverse response in tuberculosis-infected mice. Mol Med Rep. 2016; 14(2):1146-52. PMC: 4940052. DOI: 10.3892/mmr.2016.5364. View

Chatterjee N, Ojha R, Khatoon N, Prajapati V . Scrutinizing Mycobacterium tuberculosis membrane and secretory proteins to formulate multiepitope subunit vaccine against pulmonary tuberculosis by utilizing immunoinformatic approaches. Int J Biol Macromol. 2018; 118(Pt A):180-188. DOI: 10.1016/j.ijbiomac.2018.06.080. View

Fisseha M, Chen P, Brandt B, Kijek T, Moran E, Zollinger W . Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun. 2005; 73(7):4070-80. PMC: 1168616. DOI: 10.1128/IAI.73.7.4070-4080.2005. View

Gong W, Liang Y, Mi J, Xue Y, Wang J, Wang L . A peptide-based vaccine ACP derived from antigens of Mycobacterium tuberculosis induced Th1 response but failed to enhance the protective efficacy of BCG in mice. Indian J Tuberc. 2022; 69(4):482-495. DOI: 10.1016/j.ijtb.2021.08.016. View

Chaudhuri R, Kulshreshtha D, Raghunandanan M, Ramachandran S . Integrative immunoinformatics for Mycobacterial diseases in R platform. Syst Synth Biol. 2014; 8(1):27-39. PMC: 3933634. DOI: 10.1007/s11693-014-9135-9. View

Nilsson J, Grifoni A, Tarke A, Sette A, Nielsen M . PopCover-2.0. Improved Selection of Peptide Sets With Optimal HLA and Pathogen Diversity Coverage. Front Immunol. 2021; 12:728936. PMC: 8416060. DOI: 10.3389/fimmu.2021.728936. View

Muto K, Kamei N, Yoshida M, Takayama K, Takeda-Morishita M . Cell-Penetrating Peptide Penetratin as a Potential Tool for Developing Effective Nasal Vaccination Systems. J Pharm Sci. 2016; 105(6):2014-2017. DOI: 10.1016/j.xphs.2016.03.026. View

Romanova J, Krenn B, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A . Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One. 2009; 4(6):e5984. PMC: 2694350. DOI: 10.1371/journal.pone.0005984. View

Siddiqui K, Amir M, Gurram R, Khan N, Arora A, Rajagopal K . Latency-associated protein Acr1 impairs dendritic cell maturation and functionality: a possible mechanism of immune evasion by Mycobacterium tuberculosis. J Infect Dis. 2013; 209(9):1436-45. DOI: 10.1093/infdis/jit595. View

10.

Yu M, Qi R, Chen C, Yin J, Ma S, Shi W . Immunogenicity of recombinant Lactobacillus casei-expressing F4 (K88) fimbrial adhesin FaeG in conjunction with a heat-labile enterotoxin A (LTAK63) and heat-labile enterotoxin B (LTB) of enterotoxigenic Escherichia coli as an oral adjuvant in mice. J Appl Microbiol. 2016; 122(2):506-515. DOI: 10.1111/jam.13352. View

11.

Manavalan B, Shin T, Kim M, Lee G . PIP-EL: A New Ensemble Learning Method for Improved Proinflammatory Peptide Predictions. Front Immunol. 2018; 9:1783. PMC: 6079197. DOI: 10.3389/fimmu.2018.01783. View

12.

Anand R, Biswal S, Bhatt R, Tiwary B . Computational perspectives revealed prospective vaccine candidates from five structural proteins of novel SARS corona virus 2019 (SARS-CoV-2). PeerJ. 2020; 8:e9855. PMC: 7531350. DOI: 10.7717/peerj.9855. View

13.

Yu W, Hu T . Conjugation with an Inulin-Chitosan Adjuvant Markedly Improves the Immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 Fusion Protein. Mol Pharm. 2016; 13(11):3626-3635. DOI: 10.1021/acs.molpharmaceut.6b00138. View

14.

Vordermeier H, Harris D, Mehrotra P, Roman E, Elsaghier A, Moreno C . M. tuberculosis-complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein. Scand J Immunol. 1992; 35(6):711-8. DOI: 10.1111/j.1365-3083.1992.tb02979.x. View

15.

Magnan C, Zeller M, Kayala M, Vigil A, Randall A, Felgner P . High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics. 2010; 26(23):2936-43. PMC: 2982151. DOI: 10.1093/bioinformatics/btq551. View

16.

Dhanda S, Gupta S, Vir P, Raghava G . Prediction of IL4 inducing peptides. Clin Dev Immunol. 2014; 2013:263952. PMC: 3893860. DOI: 10.1155/2013/263952. View

17.

Wang N, Chen M, Wang T . Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization. J Control Release. 2019; 303:130-150. PMC: 7111479. DOI: 10.1016/j.jconrel.2019.04.025. View

18.

Maurya S, Aqdas M, Das D, Singh S, Nadeem S, Kaur G . A multiple T cell epitope comprising DNA vaccine boosts the protective efficacy of Bacillus Calmette-Guérin (BCG) against Mycobacterium tuberculosis. BMC Infect Dis. 2020; 20(1):677. PMC: 7495405. DOI: 10.1186/s12879-020-05372-1. View

19.

Mustafa A, Shaban F . Mapping of Th1-cell epitope regions of Mycobacterium tuberculosis protein MPT64 (Rv1980c) using synthetic peptides and T-cell lines from M. tuberculosis-infected healthy humans. Med Princ Pract. 2010; 19(2):122-8. DOI: 10.1159/000273073. View

20.

Mustafa A, Shaban F, Abal A, Al-Attiyah R, Wiker H, Lundin K . Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines. Infect Immun. 2000; 68(7):3933-40. PMC: 101670. DOI: 10.1128/IAI.68.7.3933-3940.2000. View